Top Markets
#1 Islamic Coin Islamic Coin +155.93%
#2 Siren Siren +36.43%
#3 Arowana Arowana +20.52%
#4 OpenEden OpenEden +19.39%
#5 Nockchain Nockchain +18.27%
#6 Venom Venom +16.20%
#7 Cysic Cysic +15.89%
#8 KUB Coin KUB Coin +12.26%
#9 Perle Perle +11.45%
#10 RedStone RedStone +11.13%
Coin of the day
Islamic Coin Islamic Coin
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Organicell Regenerative Medicine, Inc. Organicell Regenerative Medicine, Inc.

Organicell Regenerative Medicine, Inc.

OCEL
Rangering i aksjer #31539
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical... Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNAs, without the inclusion of any artificial additives or diluents. Zofin is currently undergoing Phase I/II clinical evaluation for its efficacy against COVID-19. Beyond its core drug development, Organicell also offers independent educational, promotional, and marketing solutions to various healthcare sectors, including medical, anti-aging, and regenerative service providers. The company maintains key research collaborations: one with the Centers for Disease Control and Prevention (CDC) to explore Zofin's anti-inflammatory and anti-infective capabilities in experimental influenza models, and another with Oklahoma State University to assess Zofin's potential in treating severe respiratory illnesses stemming from viruses with pandemic risk. Founded in 2011, this Miami, Florida-based company initially operated as Biotech Products Services and Research, Inc. It adopted its current name, Organicell Regenerative Medicine, Inc., in June 2018.
Aksjekurs
$1.77
Sist synkronisert: 2024-04-02
Markedsverdi
$12.89M
Endring (1 dag)
-11.50%
Endring (1 år)
0.00%
Land
US
Handel Organicell Regenerative Medicine, Inc. (OCEL)

Kategori

Healthcare
P/E-forhold for Organicell Regenerative Medicine, Inc. (OCEL)
P/E-forhold per 2026 TTM: 0
Ifølge Organicell Regenerative Medicine, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Organicell Regenerative Medicine, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.